Clozapine-induced severe mixed hyperlipidemia: a case report.
OBJECTIVE
To highlight the association between the use of clozapine and the early development of severe mixed hyperlipidemia, a condition that substantially increases the risk of cardiovascular events and other medical complications.


METHODS
Clinical information and data from investigations in a single patient were collated and reviewed in light of the literature.


RESULTS
A 47-year-old man with a background history of schizophrenia taking clozapine presented with multiple episodes of severe elevation of serum triglycerides and cholesterol with subsequent development of diabetes mellitus. His metabolic parameters normalized following discontinuation of clozapine.


CONCLUSIONS
Lipid and metabolic profiles should be closely monitored in patients receiving clozapine in order to facilitate early detection and intervention to prevent further health complications.
Ahmed
Mohamed
M
Department of Psychiatry, National University of Ireland Galway, Galway, Ireland. mohamed.ahmed@nuigalway.ie
Griffin
Damian
D
O'Toole
Ray
R
McDonald
Colm
C
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced*; D007494:Ireland; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy; D012720:Severity of Illness Index; D014280:Triglycerides / Q000097:blood
D014150:Antipsychotic Agents; D014280:Triglycerides; D002784:Cholesterol; D003024:Clozapine